Brian Bronk | Head of Business Development, Rare Diseases & Rare Blood Disorders, Global Business Development & Licensing

Brian Bronk, Head of Business Development, Rare Diseases & Rare Blood Disorders, Global Business Development & Licensing, Sanofi

Brian Bronk, Head of Business Development, Rare Diseases & Rare Blood Disorders joined the Sanofi Global Business Development organization in January 2017 as Head of External Innovation for Rare Diseases. He and his team are responsible for orchestrating the delivery of external innovation solutions that contribute to the Rare Disease and Rare Blood Disorders Research, Development and Commercial portfolios in a manner that drives a cohesive and integrated business and scientific strategy within these therapeutic areas. Prior to his roles in Business Development, Brian was a member of the Sunrise team, part of Global R&D at Sanofi.

Before joining Sanofi, Brian had been advising a number of venture capital groups and privately held life science organizations, providing input on topics ranging from research and development operations and strategy to business and corporate development. In this role, his efforts contributed to a number of successful financing rounds, as well as advancing R&D portfolios through key milestones. During his time as an independent advisor, Brian also co-founded and successfully launched Armada Therapeutics.

From 2009-2013, Brian was Vice President of Research and Development at Satori Pharmaceuticals, where he was a member of the Executive Leadership team and led the internal and external chemical sciences and drug metabolism groups. Before Satori, Brian was at Pfizer (1994-2008), rising to the level of Senior Director of Chemistry, leading groups in both Infectious Disease and Neuroscience. During his time at Pfizer, his responsibilities included contributing to R&D strategy across multiple platforms and therapeutic areas. By focusing on innovation and collaboration, Brian and his teams have been involved in the discovery of more than twenty development candidates, including the launched products Draxxin™, Convenia™, Cerina™ and Slentrol™


15th May Pre-Conference Workshops and Summits Day @ 09:20

TBC: Late preclinical and early clinical updates on Sanofi’s rare disease projects

Conference Day 1: Thursday 16th May 2019 @ 14:35

Panel discussion: Delivering on the Promise of Gene Therapy 

Making genetic therapies a reality for patientsAttendees will have the opportunity to hear from a panel of experts as they discuss the importance of commercial, scientific and clinical working together, every step of the way, from development to commercialization, to bring a new treatment to patients.
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152


Jessica Robinson 
t/ +44 (0)207 092 1150


Issa Mauthoor 
+44 (0)207 092 1257